102 related articles for article (PubMed ID: 1422320)
1. Effects of ipriflavone on bone mass and calcium metabolism in postmenopausal osteoporosis.
Agnusdei D; Adami S; Cervetti R; Crepaldi G; Di Munno O; Fantasia L; Isaia GC; Letizia G; Ortolani S; Passeri M
Bone Miner; 1992 Oct; 19 Suppl 1():S43-8. PubMed ID: 1422320
[TBL] [Abstract][Full Text] [Related]
2. Effect of chronic treatment with ipriflavone in postmenopausal women with low bone mass.
Gennari C; Adami S; Agnusdei D; Bufalíno L; Cervetti R; Crepaldi G; Di Marco C; Di Munno O; Fantasia L; Isaia GC; Mazzuoli GF; Ortolani S; Passeri M; Serni U; Vecchiet L
Calcif Tissue Int; 1997; 61 Suppl 1():S19-22. PubMed ID: 9263612
[TBL] [Abstract][Full Text] [Related]
3. Effects of 1-year treatment with ipriflavone on bone in postmenopausal women with low bone mass.
Valente M; Bufalino L; Castiglione GN; D'Angelo R; Mancuso A; Galoppi P; Zichella L
Calcif Tissue Int; 1994 May; 54(5):377-80. PubMed ID: 8062153
[TBL] [Abstract][Full Text] [Related]
4. Effect of ipriflavone on bone mass in elderly osteoporotic women.
Passeri M; Biondi M; Costi D; Bufalino L; Castiglione GN; Di Peppe C; Abate G
Bone Miner; 1992 Oct; 19 Suppl 1():S57-62. PubMed ID: 1422322
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of ipriflavone in established osteoporosis and long-term safety.
Agnusdei D; Bufalino L
Calcif Tissue Int; 1997; 61 Suppl 1():S23-7. PubMed ID: 9263613
[TBL] [Abstract][Full Text] [Related]
6. Ipriflavone and low doses of estrogens in the prevention of bone mineral loss in climacterium.
Melis GB; Paoletti AM; Bartolini R; Tosti Balducci M; Massi GB; Bruni V; Becorpi A; Ottanelli S; Fioretti P; Gambacciani M
Bone Miner; 1992 Oct; 19 Suppl 1():S49-56. PubMed ID: 1422321
[TBL] [Abstract][Full Text] [Related]
7. A double blind, placebo-controlled trial of ipriflavone for prevention of postmenopausal spinal bone loss.
Agnusdei D; Crepaldi G; Isaia G; Mazzuoli G; Ortolani S; Passeri M; Bufalino L; Gennari C
Calcif Tissue Int; 1997 Aug; 61(2):142-7. PubMed ID: 9236262
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of ipriflavone in the prevention and treatment of postmenopausal osteoporosis.
Kovács AB
Agents Actions; 1994 Mar; 41(1-2):86-7. PubMed ID: 8079827
[TBL] [Abstract][Full Text] [Related]
9. Ipriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial.
Alexandersen P; Toussaint A; Christiansen C; Devogelaer JP; Roux C; Fechtenbaum J; Gennari C; Reginster JY;
JAMA; 2001 Mar; 285(11):1482-8. PubMed ID: 11255425
[TBL] [Abstract][Full Text] [Related]
10. Ipriflavone prevents radial bone loss in postmenopausal women with low bone mass over 2 years.
Adami S; Bufalino L; Cervetti R; Di Marco C; Di Munno O; Fantasia L; Isaia GC; Serni U; Vecchiet L; Passeri M
Osteoporos Int; 1997; 7(2):119-25. PubMed ID: 9166391
[TBL] [Abstract][Full Text] [Related]
11. Effects of combined low dose of the isoflavone derivative ipriflavone and estrogen replacement on bone mineral density and metabolism in postmenopausal women.
Gambacciani M; Ciaponi M; Cappagli B; Piaggesi L; Genazzani AR
Maturitas; 1997 Sep; 28(1):75-81. PubMed ID: 9391998
[TBL] [Abstract][Full Text] [Related]
12. Design for an ipriflavone multicenter European fracture study.
Reginster JY; Bufalino L; Christiansen C; Devogelaer JP; Gennari C; Riis BJ; Roux C
Calcif Tissue Int; 1997; 61 Suppl 1():S28-32. PubMed ID: 9263614
[TBL] [Abstract][Full Text] [Related]
13. Treatment of post-menopausal osteoporosis with recombinant human growth hormone and salmon calcitonin: a placebo controlled study.
Gonnelli S; Cepollaro C; Montomoli M; Gennari L; Montagnani A; Palmieri R; Gennari C
Clin Endocrinol (Oxf); 1997 Jan; 46(1):55-61. PubMed ID: 9059558
[TBL] [Abstract][Full Text] [Related]
14. Metabolic and bone effects after administration of ipriflavone and salmon calcitonin in postmenopausal osteoporosis.
Cecchettin M; Bellometti S; Cremonesi G; Solimeno LP; Torri G
Biomed Pharmacother; 1995; 49(10):465-8. PubMed ID: 8746073
[TBL] [Abstract][Full Text] [Related]
15. Effects of ipriflavone administration on bone mass and metabolism in ovariectomized women.
Gambacciani M; Spinetti A; Cappagli B; Taponeco F; Felipetto R; Parrini D; Cappelli N; Fioretti P
J Endocrinol Invest; 1993 May; 16(5):333-7. PubMed ID: 8320424
[TBL] [Abstract][Full Text] [Related]
16. Effect of ipriflavone--a synthetic derivative of natural isoflavones--on bone mass loss in the early years after menopause.
Gennari C; Agnusdei D; Crepaldi G; Isaia G; Mazzuoli G; Ortolani S; Bufalino L; Passeri M
Menopause; 1998; 5(1):9-15. PubMed ID: 9689189
[TBL] [Abstract][Full Text] [Related]
17. Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women: a randomized double-blind placebo-controlled study.
Morabito N; Crisafulli A; Vergara C; Gaudio A; Lasco A; Frisina N; D'Anna R; Corrado F; Pizzoleo MA; Cincotta M; Altavilla D; Ientile R; Squadrito F
J Bone Miner Res; 2002 Oct; 17(10):1904-12. PubMed ID: 12369794
[TBL] [Abstract][Full Text] [Related]
18. Effects of 1-year ipriflavone treatment on lumbar bone mineral density and bone metabolic markers in postmenopausal women with low bone mass.
Ohta H; Komukai S; Makita K; Masuzawa T; Nozawa S
Horm Res; 1999; 51(4):178-83. PubMed ID: 10474019
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and safety of ipriflavone in postmenopausal women with osteopenia or osteoporosis: A systematic review and meta-analysis.
Hu Q; Long C; Wu D; You X; Ran L; Xu J; O Klineberg E; Huang S; Chen J; Ning N
Pharmacol Res; 2020 Sep; 159():104860. PubMed ID: 32407952
[TBL] [Abstract][Full Text] [Related]
20. New perspectives in the treatment of postmenopausal osteoporosis: ipriflavone.
Moscarini M; Patacchiola F; Spacca G; Palermo P; Caserta D; Valenti M
Gynecol Endocrinol; 1994 Sep; 8(3):203-7. PubMed ID: 7847106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]